A Transcriptomic Immunologic Signature Predicts Favorable Outcome in Neoadjuvant Chemotherapy Treated Triple Negative Breast Tumors

Limited therapeutic options exist for the treatment of patients with triple negative breast cancer (TNBC). Neoadjuvant chemotherapy is currently the standard of care treatment in the early stages of the disease, although reliable biomarkers of response have been scarcely described. In our study we e...

Descripción completa

Detalles Bibliográficos
Autores principales: Pérez-Pena, Javier, Tibor Fekete, Janos, Páez, Raquel, Baliu-Piqué, Mariona, García-Saenz, José Ángel, García-Barberán, Vanesa, Manzano, Aránzazu, Pérez-Segura, Pedro, Esparis-Ogando, Azucena, Pandiella, Atanasio, Gyorffy, Balázs, Ocana, Alberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930158/
https://www.ncbi.nlm.nih.gov/pubmed/31921107
http://dx.doi.org/10.3389/fimmu.2019.02802

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930158/
https://www.ncbi.nlm.nih.gov/pubmed/31921107
http://dx.doi.org/10.3389/fimmu.2019.02802

Ejemplares similares